Novo Nordisk seeks extended approval for diabetes drug in the US
The US FDA will now decide whether to expand the label for Novo Nordisk's drug Ozempic to also include a higher dose of the drug.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical firm Novo Nordisk has submitted a label expansion application for its diabetes drug Ozempic to the US Food and Drug Administration (FDA), according to a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
MEPs to shed light on shelved vaccine deals
For subscribers
